Recombinant human interferon gamma for injection

Interferon gamma; has a strong immunomodulatory function, can enhance the function of antigen presenting cells, accelerate the clearance of immune complexes and improve the phagocytic function of foreign bodies, has a bidirectional regulatory function on lymphocytes, improves antibody-dependent cytotoxic reactions, and enhances the expression of HLA class II antigens in certain immune-active cells. It has a strong inhibitory effect on the activation, proliferation and secretion of extracellular matrix of hepatic stellate cells (HSC), and can inhibit collagen synthesis and promote collagen degradation. This product has an inhibitory effect on synovial fibroblasts in patients with rheumatoid arthritis. Acute toxicity test: There was no acute toxic reaction when the human dose was injected into the tail vein and abdominal cavity of mice at 20 times and 100 times (calculated by body weight), and the human dose was injected into rats intramuscularly at 20 times and 100 times. Long-term toxicity test: Dogs were injected intramuscularly with 4 and 20 times the human dose of this product, and rats were injected intramuscularly with 4, 20 and 100 times the human dose of this product. The injections were continued for 90 days. All animals survived healthily. No toxic reactions were observed in blood and bone marrow smears, various biochemical indicators, and pathological sections of major organs.

Main ingredients: recombinant human interferon gamma;.

This product is a white or slightly yellow loose body. After dissolving, it becomes a clear liquid and does not contain insoluble matter visible to the naked eye.

This product is approved for the treatment of rheumatoid arthritis. Clinical results have shown that it is effective in the treatment of myelodysplastic syndrome, atopic dermatitis and condyloma acuminatum. The US FDA has approved it for the treatment of metastatic renal cancer, trauma, atopic dermatitis and granuloma. Japan has approved it for the treatment of renal cell carcinoma and mycosis fungoides. Europe has approved it for the treatment of rheumatoid arthritis.

This product should be used under the guidance of a clinical physician. Each bottle of the product is dissolved in 1 ml of sterile injection water and injected subcutaneously or intramuscularly. Initially, 500,000 international units (IU) are injected daily. After 3 to 4 consecutive days, if there is no obvious adverse reaction, the dose is increased to 1 million IU per day. Starting from the second month, 1.5 to 2 million IU are injected every other day. The total course of treatment is 3 months. If the course of treatment can be extended to 6 months, the effect will be better or follow the doctor's advice.

A common adverse reaction is fever, which often occurs several hours after injection and lasts for several hours and then disappears on its own. Most cases are low-grade fever (below 38°C), but a few cases have higher fever. When the patient has fever, he or she may have flu-like symptoms such as headache, muscle pain, and joint pain. Generally, there will be no fever reaction after 3 to 5 days of medication. Other adverse reactions include fatigue, loss of appetite, and nausea. Common laboratory abnormalities include leukopenia, thrombocytopenia, and elevated ALT, which are generally transient and can recover on their own. If the above-mentioned serious adverse reactions that the patient cannot tolerate occur, the dose should be reduced or the drug should be discontinued, and necessary symptomatic treatment should be given.

1. People who are known to be allergic to interferon products and products derived from E. coli. 2. People with a history of angina pectoris, myocardial infarction, or other serious cardiovascular diseases. 3. People with other serious diseases who cannot tolerate the possible adverse reactions of this product. 4. People with epilepsy and other central nervous system disorders.

The interaction between recombinant human interferon gamma and other drugs has not been systematically studied. In clinical applications, care should be taken not to use this product simultaneously with drugs that inhibit bone marrow hematopoiesis.

Store at 2-8℃ away from light.

1 million IU

Shanghai Chemowanbang Biopharma Co., Ltd.

• Founded in:

  2008-11-19

• Address:

  No. 1098, Yuegong Road, Jinshan Industrial Zone, Shanghai

• Tax NO.:

  91310000680966510Y

• Registered Funds:

  153 million yuan

• Website:

  Log in to view

• Email:

  Log in to view